Cigna Corporation

🇺🇸New York Stock Exchange
Back to all articles
Cigna Corporation stock analysis CI overview
Somewhat Bullish +45

Cigna Stock Trades Below Industry P/E: Is It Worth Holding Now?

🏢 Cigna operates through two main segments: Cigna Healthcare and Evernorth Health Services, offering medical plans and pharmacy solutions.

💰 The company has a market capitalization of $68.8 billion and trades with a forward P/E ratio of 8.61x, which is lower than the industry average of 13.45x.

📉 Shares have lost 3.4% year-to-date, yet this loss is less severe than the industry’s 13.5% decline over the same period.

🔒 Cigna holds a Zacks Rank #3 (Hold) and carries a Value Score of A based on current market analysis.

📈 The consensus estimate for 2026 earnings is pegged at $30.29 per share, suggesting a 1.5% year-over-year increase.

💵 Estimated revenue for 2026 is pinned at $284.4 billion, indicating 3.5% year-over-year growth.

📊 The company beat earnings estimates in each of the trailing four quarters, with an average surprise of 2.7%.

⚡ Adjusted income from operations rose 4% in 2025, driven by strong growth in the Evernorth Health Services segment.

🏥 Evernorth Health Services’ adjusted revenues increased 16% in 2025 to $235 billion as the company adopted a new pharmacy benefits model.

💸 Adjusted SG&A expense ratio dropped to 5.0% in 2025 due to business mix shifts and digital transformation efforts.

🤝 The quarterly dividend was increased to $1.56 per share in early 2026 from $1.51 in 2025, signaling confidence in long-term cash flow.

📉 Total benefits and expenses escalated 27% in 2024 and 12% in 2025, with the medical cost ratio deteriorating to 84.4%.

💳 The company reported a significant debt level with $30.9 billion in long-term debt at the end of 2025 compared to $7.7 billion in cash.

🩺 Investors should monitor persistent expense escalation which might weigh on margin growth despite strong operational performance.

🔍 Other medical space stocks like Catalyst Pharmaceuticals, Enovis, and USANA currently hold higher Zacks Ranks #1 (Strong Buy).

🚀 The Zacks Top 10 Stocks portfolio has gained +2,530.8% since inception in 2012, significantly outperforming the S&P 500.

Bullish Signals
  • CI shares have lost only 3.4% year-to-date, significantly outperforming the industry's average 13.5% decline.
  • The company trades at a forward P/E ratio of 8.61x, which is well below the industry average of 13.45x, indicating an attractive valuation.
  • Cigna has beat earnings estimates in each of the trailing four quarters with an average surprise of 2.7%.
  • Adjusted income from operations rose 4% year-over-year to 2025, driven by strong growth in the Evernorth Health Services segment.
  • Evernorth Health Services 2025 adjusted revenues increased 16% year-over-year to $235 billion.
  • The company successfully repurchased 11.9 million shares for approximately $3.6 billion in 2025 to support shareholder value.
  • The board increased the quarterly dividend to $1.56 per share in early 2026, up from $1.51 in 2025, signaling confidence in cash flow.
  • Cigna maintains a Value Score of A and holds a Zacks Rank #3 (Hold), suggesting solid prospects.
  • New transformative pharmacy benefits model will lower out-of-pocket costs by passing manufacturer discounts directly to customers starting in 2027.
Risk Factors
  • The company's total benefits and expenses escalated significantly, witnessing a year-over-year increase of 27% in 2024 and 12% in 2025 due to higher pharmacy, medical costs, and other benefit expenses.
  • The persistent escalation of expenses might weigh on the company's margin growth, with the medical cost ratio deteriorating 120 basis points year over year to 84.4% in 2025.
  • Cigna has been grappling with a significant debt level, holding long-term debt of $30.9 billion at the end of 2025, which is significantly higher than its cash balance of $7.7 billion.
  • The elevated leverage level is likely to keep pressure on the company's interest expenses going forward.
  • Cigna's shares have lost 3.4% year to date (YTD), even though they outperformed the industry's average 13.5% decline, suggesting relative weakness within a bearish sector.
Full Analysis
Cigna Group Inc. trades at a forward price-to-earnings ratio of 8.61x, which is notably lower than the industry average of 13.45x, suggesting a potentially undervalued position despite its shares declining 3.4% year to date against an industry decline of 13.5%. The company operates through two primary segments, Cigna Healthcare and Evernorth Health Services, with a market capitalization of $68.8 billion. Analysts maintain a Zacks Rank #3 (Hold) for the stock, supported by a strong A Value Score and a consensus estimate projecting 2026 earnings at $30.29 per share, representing a 1.5% year-over-year increase, while revenues are expected to grow 3.5% to $284.4 billion. Cigna has demonstrated consistent performance by beating earnings estimates in each of the last four quarters with an average surprise of 2.7%, and its adjusted income from operations rose 4% in 2025 driven primarily by growth in the Evernorth Health Services segment, which reported $235 billion in revenue for the year. Strategic initiatives are aimed at enhancing shareholder value and operational efficiency, including a share repurchase program where the company bought back 11.9 million shares for approximately $3.6 billion in 2025, and an increase in the quarterly dividend to $1.56 per share in early 2026. The Evernorth Health Services division introduced a transformative pharmacy benefits model that passes manufacturer discounts directly to customers at the point of sale, with Cigna Healthcare planning to adopt this for fully insured customers starting in 2027. These business mix shifts and digital transformation efforts reduced the adjusted selling, general, and administrative expense ratio to 5.0% in 2025, although the company expects adjusted operating income to reach at least $7.95 billion by 2026. However, investors should monitor several headwinds that could impact margin growth. Total benefits and expenses escalated significantly, increasing by 27% in 2024 and 12% in 2025 due to higher pharmacy and service costs, with the medical cost ratio deteriorating 120 basis points year over year to 84.4% in 2025. Additionally, Cigna faces elevated leverage levels, holding long-term debt of $30.9 billion at the end of 2025 compared to a cash balance of $7.7 billion, which may sustain pressure on interest expenses going forward. The article concludes by noting other better-ranked stocks in the broader medical space, such as Catalyst Pharmaceuticals and Enovis Corporation, which hold a Zacks Rank #1 (Strong Buy) with more robust recent earnings beats compared to Cigna's current Hold status.